Poxel ROE 2025

Mis teeb Poxel?

Poxel SA is a biopharmaceutical company focused on developing drugs for the treatment of metabolic disorders, particularly type 2 diabetes. The company was founded in Lyon, France, in 2009. Poxel SA's business model is based on the targeted development of drugs for the treatment of metabolic disorders with high medical demand and large market potential. The company focuses on identifying drug candidates that are highly specific and effective while also having a favorable safety profile. Poxel SA collaborates closely with academic research and the industry to leverage the latest knowledge and technologies in drug development. Over the years, Poxel SA has become a leading company in metabolism medicine, with an extensive product pipeline of promising drug candidates. The product range includes both preclinical and clinical candidates, as well as products in advanced stages of clinical development. One of Poxel SA's main products is Imeglimin, a drug for the treatment of type 2 diabetes. Imeglimin is a new active ingredient that acts on the metabolic disorder in a novel way and improves the body's glucose metabolism. The drug is currently in the final phase of clinical development and has shown promising results in previous studies. Another promising product from Poxel SA is PXL770, a drug for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). PXL770 is a novel active ingredient that acts on the body's AMP-activated protein kinase system and regulates lipid and glucose metabolism. The drug is still in the clinical development phase but has already shown promising results. Another promising product group from Poxel SA are the adenosine monophosphate (AMP) activators, which are also being developed for the treatment of metabolic disorders such as type 2 diabetes and fatty liver disease. The AMP activators act on the body's AMP-activated protein kinase system and regulate lipid and glucose metabolism. Poxel SA also works closely with partners in the pharmaceutical industry to develop and bring innovative drug candidates to the market. The company has partnerships with leading companies such as Sumitomo Dainippon Pharma, Roivant Sciences, and Servier to expand and diversify its product pipeline. Overall, Poxel SA is an emerging company in metabolism medicine, focusing on the development of innovative drugs for the treatment of metabolic disorders. With a strong product pipeline and proven collaboration with academia and the industry, Poxel SA is a promising player in this growing market. Poxel ist eines der beliebtesten Unternehmen auf Eulerpool.com.